This Nottingham-based company works with research organisations to develop drugs for illnesses such as cancer, respiratory disease and Alzheimer’s, and in October last year announced a collaboration with Malaysian company, Viramatix, to develop anti-influenza medicine. Simon Hirst, 52, started Sygnature in 2004. Customers in America, Germany, Denmark and Australia lifted overseas sales to £5.8m in 2016, when it also took a stake in Cheshire-based Peak Proteins.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
Year2017
Rank93
CompanySygnature Discovery
ActivityNew drug researcher
LocationNottingham
2 yr av intl sales growth % pa32.30%
International sales £000s5,827
Total sales £000s12,330
Staff133
Founded2004
Websitewww.sygnaturediscovery.com

If applicable:

* Supplied by company † Annualised figure